1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2. US Food and Drug Administration.FDA: Atezolizumab Prescribing Information (2018). Accessed February 10 2020.
3. US Food and Drug Administration.FDA: Durvalumab Prescribing Information (2018). Accessed February 10 2020.
4. US Food and Drug Administration.FDA: Pembrolizumab Prescribing Information (2019). Accessed February 10 2020.
5. US Food and Drug Administration.FDA: Nivolumab Prescribing Information (2019). Accessed February 10 2020.